These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11996085)

  • 21. Tuftsin-bearing liposomes in treatment of macrophage-based infections.
    Agrawal AK; Gupta CM
    Adv Drug Deliv Rev; 2000 Mar; 41(2):135-46. PubMed ID: 10699310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.
    Prajapati VK; Awasthi K; Gautam S; Yadav TP; Rai M; Srivastava ON; Sundar S
    J Antimicrob Chemother; 2011 Apr; 66(4):874-9. PubMed ID: 21393222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
    Yardley V; Croft SL
    Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophage specific drug delivery in experimental leishmaniasis.
    Basu MK; Lala S
    Curr Mol Med; 2004 Sep; 4(6):681-9. PubMed ID: 15357216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies.
    Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK
    Nanomedicine (Lond); 2015; 10(7):1093-109. PubMed ID: 25929567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of liposomal andrographolide to L. donovani-infected macrophages in vivo.
    Sinha J; Mukhopadhyay S; Das N; Basu MK
    Drug Deliv; 2000; 7(4):209-13. PubMed ID: 11195427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 28. Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS.
    Mastroianni A
    Infez Med; 2004 Sep; 12(3):197-204. PubMed ID: 15711134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.
    Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR
    Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis.
    Berman JD; Ksionski G; Chapman WL; Waits VB; Hanson WL
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1978-80. PubMed ID: 1416890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpressed Macrophage Mannose Receptor Targeted Nanocapsules- Mediated Cargo Delivery Approach for Eradication of Resident Parasite: In Vitro and In Vivo Studies.
    Asthana S; Gupta PK; Jaiswal AK; Dube A; Chourasia MK
    Pharm Res; 2015 Aug; 32(8):2663-77. PubMed ID: 25715698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal amphotericin B.
    Sundar S
    Lancet; 2001 Mar; 357(9258):801-2. PubMed ID: 11253992
    [No Abstract]   [Full Text] [Related]  

  • 34. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.
    Pal S; Ravindran R; Ali N
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis.
    Kansal S; Tandon R; Dwivedi P; Misra P; Verma PR; Dube A; Mishra PR
    J Antimicrob Chemother; 2012 Nov; 67(11):2650-60. PubMed ID: 22872448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting of urea stibamine encapsulated in liposomes to reticuloendothelial system for the treatment of experimental leishmaniasis.
    Das N; Mahato SB; Naskar K; Ghosh DK; Basu MK
    Biochem Med Metab Biol; 1990 Apr; 43(2):133-9. PubMed ID: 2346669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice.
    Agarwal A; Kandpal H; Gupta HP; Singh NB; Gupta CM
    Antimicrob Agents Chemother; 1994 Mar; 38(3):588-93. PubMed ID: 8203859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
    Sinha R; Roychoudhury J; Palit P; Ali N
    Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
    Paila YD; Saha B; Chattopadhyay A
    Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B.
    Khan MA; Syed FM; Nasti HT; Saima Dagger K; Haq W; Shehbaz A; Owais M
    J Drug Target; 2003 Feb; 11(2):93-9. PubMed ID: 12881195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.